LILeonid K. Isakov

Leonid K. Isakov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leonid K. Isakov has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Academic schools of internal and preventive medicine: vectors for the development of physician professionalism

    by O. M. Drapkina, S. Yu. Astanina, R. N. Shepel, D. R. Akberova, R. K. Ashurbayeva, Z. Z. Balkizov, O. L. Barbarash, I. E. Belaya, T. V. Bolotnova, T. P. Vasilyeva, et al.

    This article defines the role of academic schools of internal and pre­ven­tive medicine in the unified educational environment for training phy­sicians in the field of internal medicine. The 5 th International Re­search and Practice Forum "Academic Schools of Internal and Pre­ven­tive Medicine" is analyzed in relation to the development of a unified edu­ca­tional environment for training general practitioners and internists. Within the unified educational environment for training general prac­titioners and internists, academic schools of internal and preventive medicine act as a system-­forming factor, ensuring the implementation of the Forum's guiding idea: "A Unified Educational Environment Is a Vector for the Development of Specialist Professionalism".


  • Open Access

    Role of physical training in cardiac rehabilitation in patients with congestive heart failure and type 2 diabetes mellitus

    by М. Н. Синькова, L. K. Isakov, E. Yu. Plotnikova, O. L. Barbarash

    Introduction. Currently, the effectiveness of cardiac rehabilitation of patients with comorbid CHF using physical training when prescribing optimal drug therapy, including SGLT2 drugs, has not been studied.Aims. To study the effect of controlled physical training on the quality of life and prognosis of patients with CHF comorbid with type 2 diabetes mellitus against the background of rational pharmacotherapy.Materials and methods. The study included 74 patients with CHF against the background of type 2 diabetes mellitus, receiving optimal drug therapy, with mandatory intake of SGLT2 drugs. Two groups were formed using the simple randomization method: “Physical training” (n = 35) – basic drug therapy supplemented by a program of controlled physical training and “Standard drug therapy” (n = 37) – only basic drug therapy. Patients in the standard drug therapy group were recommended regular aerobic physical activity of moderate intensity for 30–60 minutes at least 5 days a week.Results. In the Physical Training group, after 12 months, an increase in the distance according to the results of the 6-minute walk test by 39.6% (on average 407.2 meters) was registered, in the Standard Drug Therapy group, physical tolerance increased by 12.2% (324.5 meters) (p = 0.002). According MLHFQ questionnaire in patients with CHF, the results were obtained that characterize the high social adaptation of patients during physical training in comparison with standard pathogenetic drug therapy. Thus, the MLHFQ indicator in the Physical Training group changed by an average of 25.2 points, and in the Standard Drug Therapy group – by 5.7 points, amounting to 37.3 ± 5.9 in the Physical Training group, and 58.2 ± 2.1 in the Standard Drug Therapy group (p = 0.001).Conclusions. Physical training in patients with CHF associated with type 2 diabetes mellitus against the background of optimal drug therapy leads to an increase in the distance according to the results of the 6-minute walk test and contributes to an improvement in the quality of life.

  • Open Access

    Impact of controlled physical training on clinicopathological and psychophysiological features of patients with chronic heart failure and type 2 diabetes

    by М. Н. Синькова, L. K. Isakov, E. Yu. Plotnikova, O. L. Barbarash

    Aim. To evaluate the effectiveness of long-term (five-year) supervised physical exercise in patients with chronic heart failure (CHF) following myocardial infarction (MI) and type 2 diabetes mellitus (T2DM).Materials and Methods. The study included 88 patients with CHF of functional class II-III after MI and concomitant T2DM. In addition to standard medication therapy, patients in the main group (n = 42) performed regular moderate-intensity physical exercises for 30−60 minutes at least 5 days a week. The control group consisted of 46 patients who received standard medication therapy. Patients in both groups had similar clinical and demographic characteristics. After 5 years of follow-up, we assessed the incidence of a composite endpoint (death, MI, emergency myocardial revascularization, acute CHF decompensation), quality of life (measured by the SF36 questionnaire), levels of anxiety and depression (measured by the HADS questionnaire), and levels of fatigue (measured by the MFI-20 questionnaire). By the end of the five-year observation period, data were available for 40 patients in the main group (11 patients were excluded from the study due to discontinuation of regular physical exercise) and 42 patients in the control group.Results. The incidence of the composite endpoint was 55.2% and 80.9% in main and control group, respectively (p = 0.038). Regular physical exercise over the five-year period was associated with a higher quality of life according to the SF36 questionnaire (64.5 [63.1; 67.8] vs. 49.2 [48.4; 49.8], p = 0.001), lower levels of anxiety (5.8 [5.1; 7.7] vs. 8.0 [6.8; 9.2], p = 0.042) and depression (2.9 [2.2; 4.2] vs. 10.7 [10.5; 12.3], p = 0.001) according to the HADS questionnaire, and lower levels of general fatigue according to the MFI-20 questionnaire (9.1 [8.5; 11.2] vs. 15.1 [14.5; 15.4], p = 0.019).Conclusion. Long-term regular physical exercise in patients with CHF and T2DM improves cardiovascular outcomes and psychological status of patients.

  • Open Access

    “Dark and bright sides” of Gilbert’s syndrome

    by E. Yu. Plotnikova, М. Н. Синькова, L. K. Isakov

    Gilbert’s syndrome, also known as benign hyperbilirubinemia, was described more than 100 years ago. It has usually been considered a physiological abnormality characterized by a mild elevation of the systemic level of unconjugated bilirubin, in the absence of any underlying liver or overt RBC hemolysis. The molecular basis of Gilbert’s syndrome lies in the impairment of the conjugation of bilirubin with glucuronic acid in the hepatocytes, which is mediated by a specific hepatic enzyme named bilirubin-UDP-glucuronosyl transferase 1A1 that forms bilirubin diglucuronoside. Clearance of various xenobiotics, which are not substrates for glucuronosylation, is impaired in patients with Gilbert’s syndrome; their detailed list is provided in the article. Fatigue, asthenia, and various vaguely defined dyspeptic complaints attributed to Gilbert’s syndrome in the past are no longer considered a part of this condition, and proper evaluation of possible causes is required in these cases. Since the re-discovery of the potent antioxidant effects of bilirubin in the late 1980s, as well as the multiple intracellular signalling pathways affected by bilirubin, an ever-increasing body of evidence suggests that individuals with Gilbert’s syndrome may benefit from the mild hyperbilirubinemia and are actually protected from the development of a wide range of “diseases of civilization”, such as cardiovascular diseases, certain cancers, and autoimmune or neurodegenerative diseases. Gilbert’s syndrome is defined phenotypically, and therefore not according to predisposing genetic markers, as the elevation of serum unconjugated bilirubin concentration above the upper limit of normal, with no laboratory signs of hemolysis or liver damage. This review analyses the current state of medical knowledge given recent discoveries in this rapidly developing field, as well as their possible clinical significance, and provides a new perspective on this condition.

  • Open Access

    CLINICAL AND PROGNOSTIC FEATURES OF ELDERLY PATIENTS WITH UNSTABLE ANGINA PECTORIS UNDERGOING CONSERVATIVE TREATMENT DEPENDING ON LEFT VENTRICULAR EJECTION FRACTION

    by Natalia B. Lebedeva, Leonid K. Isakov, Margarita N. Sinkova, Nikolay I. Tarasov, Lilia V. Kuznetsova

    Highlights High cardiovascular morbidity and mortality in the Russian Federation and in Kuzbass is mainly due to high number of elderly and senile patients; it simply reflects the current demographic situation in the country. Elderly and senile patients with acute coronary syndrome (ACS) account for 50% of hospitalized patients. In real clinical practice, a significant number of elderly patients with ACS receive conservative treatment, whereas the prognosis in this cohort is determined by the development of recurrent coronary events and the progression of heart failure. Due to small number of patients older than 75-80 years included in randomized clinical trials, there are certain gaps in the management of elderly patients with ACS and heart failure. Obviously, elderly patients require a special approach to patient management, taking into account the complexity of clinical and anamnestic factors affecting the prognosis. AbstractAim. To study clinical and prognostic features of elderly patients with unstable angina pectoris undergoing conservative treatment depending on left ventricular ejection fraction (LVEF).Methods. 130 elderly patients, with mean age of 82 (77; 89) years, hospitalized for unstable angina with a GRACE score of less than 140 to a vascular center in Kemerovo were included in the study. During hospitalization, standard laboratory and instrumental studies were performed, except coronary angiography. The quality of life was assessed using the EQ-5D 3L questionnaire. After 12 months, patient compliance with treatment recommendations, primary and secondary endpoints, and quality of life were analyzed.Results. All patients were diagnosed with heart failure, 50 (38.5%) patients presented with LV EF less than 40% (the group I), 80 (61.5%) patients presented with LV EF more than 40% (the group II). The groups were comparable in gender, age, presence of multifocal of atherosclerotic disease, prevalence of aortic stenosis, arrhythmias and comorbidities. Women predominated in both groups, and arterial hypertension was noted in all patients. In the group I, a history of myocardial infarction, coronary revascularization, and NYHA FC III were more common (p0.05). Almost all patients were on triple neurohumoral blockade (beta-blockers, renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists) for heart failure and dual antiplatelet therapy. One year later, 85.2% of patients in the group I and 90% of patients in the group II were taking all prescribed medication at low or medium therapeutic doses (without the need for drug titration). The overall mortality in the groups was 46% and 37.5%; cardiovascular deaths accounted for 32% and 30%, respectively (p>0.05). There were no differences in the frequency of endpoints (hospitalization, stroke, acute coronary syndrome, coronary revascularization) between the groups. The level of quality of life remained low in both groups.Conclusion. In patients over 75 years hospitalized for unstable angina, main clinical and anamnestic characteristics, annual prognosis and quality of life do not depend on LV EF, whereas the need for coronary revascularization during the 1 year remains high.

  • Open Access

    LONG-TERM EFFECTS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS ON CORONARY HEART DISEASE IN PATIENTS WITH MULTIVESSEL STENOTIC CORONARY ARTERY ATHEROSCLEROSIS AND ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: POST-TRIAL ANALYSIS

    by Маргарита Николаевна Синькова, Леонид Константинович Исаков, Максим Алексеевич Синьков, Екатерина Юрьевна Плотникова

    Введение. Многочисленные исследования показали отчетливую связь между определенными диетическими жирами и смертностью. Однако данные о специфических пищевых жирах и смертности среди пациентов с кардиометаболическими заболеваниями остаются неоднозначными. Холестерин липопротеинов низкой плотности считается основной мишенью для профилактики и лечения атеросклеротических сердечно-сосудистых заболеваний. Вместе с тем у многих пациентов по-прежнему сохраняются остаточные сердечно-сосудистые риски, даже если холестерин липопротеинов низкой плотности достигает целевого уровня. Новые данные свидетельствуют о том, что повышенный уровень триглицеридов или холестерина липопротеинов, богатых триглицеридами, является одним из важных компонентов остаточного сердечно-сосудистого риска. Было показано, что жирные кислоты омега-3 являются одним из эффективных препаратов для снижения триглицеридов.  Цель настоящего исследования состояла в том, чтобы оценить связь между длительным многолетним потреблением омега-3 жирных кислот и прогнозом пациентов с ишемической болезнью сердца на фоне многососудистого поражения коронарного русла после перенесенного инфаркта миокарда. Материалы и методы. Авторами проведено посттриальное наблюдение пациентов спустя 5 лет после окончания 12-месячного исследования эффективности и безопасности приема препаратов ω-3-ПНЖК в дозе 1000 мг/сут. на течение ишемической болезни сердца на фоне многососудистого поражения коронарного русла после перенесенного инфаркта миокарда. Ретроспективно все ранее участвовавшие в исследовании пациенты были разделены на три группы: 1 группа – пациенты, не получавшие ω-3-ПНЖК в течение основного исследования (информация получена о 111 пациентах), вторая группа – пациенты, получавшие ω-3-ПНЖК в течение исследования, но не принимавшие (или принимавшие эпизодически) препарат ω-3-ПНЖК в течение 5 лет после окончания исследования (получена информация о судьбе 61 такого пациента) и пациенты, принимавшие исследуемый препарат в ходе исследования и продолжившие его постоянный прием с перерывами не более двух недель, в течение 5 лет после окончания исследования (получена информация о 32 больных).  Результаты и обсуждение. После прекращения приема препарата ω-3-ПНЖК в течение 5 лет полностью нивелируется его клиническая эффективность, зарегистрированная после 12 месяцев его постоянного приема, при этом достигнутый положительный эффект спустя 12 месяцев наблюдения при продолжении постоянного приема ω-3-ПНЖК на протяжении последующих пяти лет не только не ускользает, но и имеет кумулятивный характер (Р≤0,02-0,03).  Нами констатирована важность именно длительного, желательно – пожизненного ω-3-ПНЖК в дозе 1000 мг в изучаемой когорте пациентов. Выводы. Результаты настоящего исследования свидетельствуют о том, что более низкая смертность от всех причин у пациентов с ишемической болезнью сердца на фоне многососудистого поражения коронарного русла после перенесенного инфаркта миокарда. может быть связана с потреблением ω-3-ПНЖК в дозе 1000 мг.

  • Open Access

    Features of laboratory parameters in the new coronavirus infection COVID-19 against the background of diabetes mellitus and chronic heart failure

    by E. Yu. Plotnikova, L. K. Isakov, М. Н. Синькова, A. Yu. Tarasova, V. N. Zolotukhina

    Introduction. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a pandemic by the World Health Organization (WHO) in March 2020. New waves of different virus genotypes regularly roll across the globe. Recent studies show the most serious prognosis for patients with known cardiovascular disease, indicating a possible relationship between SARS-CoV-2 infection and an increase in new cases of cardiovascular diseases and diabetes regardless of the severity of the pathology. If this trend is true, with hundreds of millions of infected patients the disease burden might presage a potentially alarming rise of cardiovascular diseases and diabetes in the future.The aim is to study the laboratory test results of patients with novel coronavirus infection COVID-19 with underlying type 2 diabetes mellitus (DM) and chronic heart failure.Materials and methods. A total of 51 patients with a verified diagnosis of moderately severe novel coronovirus infection COVID-19 with underlying type 2 diabetes and chronic heart failure were included in the study. All patients underwent quantitative laboratory blood tests. Correlation analysis was carried out using the Spearman’s rank correlation coefficient.Results and discussion. In our opinion, the most interesting were numerous correlations between glucose levels and internal organs and systems dysfunction markers: with bilirubin levels, international normalized ratios, creatinine levels, with carbon dioxide (ctCO2 ) levels, bases (BE) levels, with the bicarbonate (HCO3 act) levels. The most pronounced (rs = 0.74) was the correlation between glucose levels and basophil counts, which may suggest a possible effect of hypersensitivity mechanisms on the severity of hyperglycemia in patients with COVID-19.Conclusions. The hyperglycemia level indicates the severity of not only metabolic acidosis, but also the internal organs and systems dysfunction in patients with novel coronavirus infection COVID-19 with underlying type 2 diabetes and heart failure.

  • Open Access

    Cardiology Research Institute, Tomsk National Research Medical Center

    by E. V. Grakova, K. V. Kopyeva, A. T. Teplyakov, L. K. Isakov, М. Н. Синькова, N. I. Tarasov

    Aim. To assess the prognostic role of cardiac biomarkers (galectin-3, soluble ST2 (sST2), and N-terminal pro-brain natriuretic peptide (NT-proBNP)) in risk stratification of adverse cardiovascular events (CVEs) in patients with heart failure (HF) after implantation of an automatic implantable cardioverter-defibrillator (AICD) within 12-month follow-up period.Material and methods. The study included 57 patients (men, 41; mean age, 65 (59; 68) years) with coronary artery disease and NYHA class II-III HF with left ventricular ejection fraction of 34 [26; 40]%. All patients were implanted with AICD. Serum levels of NT-proBNP, sST2, and galectin-3 were determined by enzyme immunoassay prior to AICD implantation.Results. It has been established that in order to stratify the risk of unfavorable HF in patients after AICD implantation for 12-month follow-up, all three studied biomarkers can be considered as prognostic factors. Thus, an increase in the level of NT-proBNP ≥1046,6 pg/ml (AUC=0,68; p=0,009), sST2 ≥34,43 ng/ml (AUC=0,78; pConclusion. The determination of the combination of galectin-3 and sST2 can potentially help identify a group of patients with HF after AICD implantation with a high risk of adverse CVEs for intensification and optimization of treatment.


  • Open Access

    Asthenia and fatigue in hyperammonemia: etiopathogenesis and methods of correction

    by E. Yu. Plotnikova, М. Н. Синькова, L. K. Isakov

    Asthenia and fatigue are the most common syndromes in patients with liver disease, which significantly affects their quality of life. The prevalence of fatigue in chronic liver diseases is from 50% to 85%. While some progress has been made in understanding the processes that can cause fatigue in general, the underlying causes of fatigue associated with liver disease remain not well understood. In particular, many data suggest that fatigue associated with liver disease likely results from changes in neurotransmission in the brain against the background of hyperammonemia. Hyperammonemia is a metabolic state characterized by an increased level of ammonia, a nitrogen-containing compound. The present review describes hyperammonemia, which is likely important in the pathogenesis of fatigue associated with liver disease. Ammonia is a potent neurotoxin, its elevated blood levels can cause neurological signs and symptoms that can be acute or chronic, depending on the underlying pathology. Hyperammonemia should be recognized early, and immediately treated to prevent the development of life-threatening complications, such as, swelling of the brain and coma. The article gives pathophysiological mechanisms of influence of hyperammonemia on state of psychovegetative status of patients with liver diseases, also lists basic principles of treatment. A significant part of the article is devoted to L-ornithine-L-aspartate, which is effective in asthenia and fatigue to reduce the level of hyperammonemia through a variety of well-studied mechanisms in chronic liver diseases.


  • Open Access

    New approach for the rehabilitation of patients with chronic heart failure associated with type 2 diabetes

    by М. Н. Синькова, L. K. Isakov, М. А. Синьков, E. Yu. Plotnikova, E. N. Gulyaeva

    Новое в реабилитации больных с хронической сердечной недостаточностью, ассоциированной с сахарным диабетом 2-го типа